Viewing Study NCT00964795

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:13 PM
Ignite Modification Date: 2026-02-03 @ 1:24 AM
Study NCT ID: NCT00964795
Status: COMPLETED
Last Update Posted: 2015-03-23
First Post: 2009-08-20
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)
Sponsor: Regeneron Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Neovascular Age-related Macular Degeneration View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Eyes View
None Neovascular View
None Macular Degeneration View
None Retina View
None AMD View
None VEGF Trap-Eye View
None Best Corrected Visual Acuity View